Your browser doesn't support javascript.
loading
Impact of drug combination of clopidogrel and pantoprazole In the prognosis of patients with transient ischemic attack
Pakistan Journal of Pharmaceutical Sciences. 2017; 30 (1): 217-221
en Inglés | IMEMR | ID: emr-185762
ABSTRACT
The study aimed to investigate the impact of clopidogrel combined with proton pump inhibitors [PPI] pantoprazole treatment on the prognosis of patients with transient ischemic attack [TIA]. A total of 478 cases of TIA patients treated with clopidogrel were randomly assigned half to clopidogrel combined with pantoprazole treatment and the control groups [clopidogrel treatment alone] from January 2012 to January 2014. The platelet aggregation before and after treatment and cerebrovascular events incidence within 90 days were compared and analyzed. Multivariate analysis was used to estimate the incidence of cerebrovascular events within 90 days. The platelet aggregation rate before treatment was 73.2 +/- 6.1% in the treatment group, 74.1 +/- 8.8% in the control group. The platelet aggregation rate after treatment was 38.1 +/- 10.7% in the treatment group, 36.8 +/- 9.7% in the control group. The platelet aggregation before and after treatments between the two groups had not significant difference [P>0.05]. The incidence of cerebrovascular events within 90 days [11.7% in the treatment group, 9.6% in the control group] between the two groups had not significant difference [P>0.05]. Multivariate analysis showed that the incidence of cerebrovascular events within 90 day was associated with hypertension [P=0.008], diabetes [P=0.000], hyperlipidemia [P=0.002] and ABCD2 score >3 points [P=0.000]. Clopidogrel combined with pantoprazole treatment had no significant effect on the prognosis of TIA patients
Asunto(s)
Buscar en Google
Índice: IMEMR (Mediterraneo Oriental) Asunto principal: Ticlopidina / Inhibidores de Agregación Plaquetaria / Progresión de la Enfermedad / Quimioterapia Combinada / 2-Piridinilmetilsulfinilbencimidazoles / Antagonistas del Receptor Purinérgico P2Y Límite: Anciano / Femenino / Humanos / Masculino Idioma: Inglés Revista: Pak. J. Pharm. Sci. Año: 2017

Similares

MEDLINE

...
LILACS

LIS

Buscar en Google
Índice: IMEMR (Mediterraneo Oriental) Asunto principal: Ticlopidina / Inhibidores de Agregación Plaquetaria / Progresión de la Enfermedad / Quimioterapia Combinada / 2-Piridinilmetilsulfinilbencimidazoles / Antagonistas del Receptor Purinérgico P2Y Límite: Anciano / Femenino / Humanos / Masculino Idioma: Inglés Revista: Pak. J. Pharm. Sci. Año: 2017